VINC

NASDAQ

Vincerx Pharma Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2025

$0.10-0.18 (-64.86%)

News25/Ratings6

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's lead product candidate is VIP152 that is in Phase I clinical trials to treat solid tumors. Its preclinical stage product candidates include VIP217 for solid tumors; VIP236 to treat multiple solid tumors; VIP943 for the treatment of leukemia and myelodysplastic syndrome; and VIP924 for treating B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Latest news

25 items

268dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Vincerx Pharma Inc.
SCHEDULE 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)
281dSEC
SEC Form DEFA14A filed by Vincerx Pharma Inc.
DEFA14A - Vincerx Pharma, Inc. (0001796129) (Filer)
281dPR
Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal
Revised Potential Distribution Range of $0.03 to $0.07 per sharebased on current estimates and assumptions Failure to approve Dissolution Proposal on a timely basis will result in continued operating costs and further reduce or eliminate any potential distributions to stockholders SAN MATEO, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC:VINC) today announced that the re-convened Special Meeting of Stockholders to consider a proposal to approve the liquidation and dissolution of Vincerx (the "Dissolution Proposal"), which was originally scheduled for earlier today, has again been adjourned, this time until 10:00 a.m., Pacific time, on August 27, 2025 via li
290dSEC
SEC Form DEFA14A filed by Vincerx Pharma Inc.
DEFA14A - Vincerx Pharma, Inc. (0001796129) (Filer)
290dSEC
SEC Form 8-K filed by Vincerx Pharma Inc.
8-K - Vincerx Pharma, Inc. (0001796129) (Filer)
290dPR
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders
Potential Distribution Range of $0.04 to $0.08 per share of outstanding stock based on current estimates and assumptions, including timely approval of Distribution Proposal Failure to approve Dissolution Proposal will reduce or eliminate any potential distributions to stockholders SAN MATEO, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC:VINC) today announced updated information regarding the Special Meeting of Stockholders of the Company (the "Special Meeting") to consider the proposal to approve the dissolution and liquidation of the Company pursuant to the Plan of Liquidation and Dissolution (the "Dissolution Proposal"). The Special Meeting was adjourned to 10:0
309dSEC
SEC Form DEFA14A filed by Vincerx Pharma Inc.
DEFA14A - Vincerx Pharma, Inc. (0001796129) (Filer)
309dPR
Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal
SAN MATEO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC:VINC) today announced that the Special Meeting of Stockholders to consider a proposal to approve the liquidation and dissolution of Vincerx (the "Dissolution Proposal"), which was originally scheduled for earlier today, has been adjourned until 10:00 a.m., Pacific time, on July 16, 2025 via live audio webcast at www.virtualshareholdermeeting.com/VINC2025SM2. The adjournment will allow Vincerx more time to solicit the votes needed to approve the Dissolution Proposal. Vincerx is urging ALL stockholders to vote IMMEDIATELY FOR the Dissolution Proposal. Vincerx's board of directors unanimously recommends that stoc
321dSEC
SEC Form DEFA14A filed by Vincerx Pharma Inc.
DEFA14A - Vincerx Pharma, Inc. (0001796129) (Filer)
343dSEC
SEC Form 10-Q filed by Vincerx Pharma Inc.
10-Q - Vincerx Pharma, Inc. (0001796129) (Filer)
343dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Vincerx Pharma Inc.
SCHEDULE 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)
346dSEC
SEC Form DEF 14A filed by Vincerx Pharma Inc.
DEF 14A - Vincerx Pharma, Inc. (0001796129) (Filer)
354dSEC
SEC Form EFFECT filed by Vincerx Pharma Inc.
EFFECT - Vincerx Pharma, Inc. (0001796129) (Filer)
354dSEC
SEC Form EFFECT filed by Vincerx Pharma Inc.
EFFECT - Vincerx Pharma, Inc. (0001796129) (Filer)
354dSEC
SEC Form EFFECT filed by Vincerx Pharma Inc.
EFFECT - Vincerx Pharma, Inc. (0001796129) (Filer)
357dSEC
SEC Form S-8 POS filed by Vincerx Pharma Inc.
S-8 POS - Vincerx Pharma, Inc. (0001796129) (Filer)
357dSEC
SEC Form S-8 POS filed by Vincerx Pharma Inc.
S-8 POS - Vincerx Pharma, Inc. (0001796129) (Filer)
357dSEC
SEC Form S-8 POS filed by Vincerx Pharma Inc.
S-8 POS - Vincerx Pharma, Inc. (0001796129) (Filer)
357dSEC
SEC Form S-8 POS filed by Vincerx Pharma Inc.
S-8 POS - Vincerx Pharma, Inc. (0001796129) (Filer)
357dSEC
SEC Form S-8 POS filed by Vincerx Pharma Inc.
S-8 POS - Vincerx Pharma, Inc. (0001796129) (Filer)
357dSEC
SEC Form POS AM filed by Vincerx Pharma Inc.
POS AM - Vincerx Pharma, Inc. (0001796129) (Filer)
357dSEC
SEC Form POS AM filed by Vincerx Pharma Inc.
POS AM - Vincerx Pharma, Inc. (0001796129) (Filer)
357dSEC
SEC Form POS AM filed by Vincerx Pharma Inc.
POS AM - Vincerx Pharma, Inc. (0001796129) (Filer)
358dSEC
SEC Form PRE 14A filed by Vincerx Pharma Inc.
PRE 14A - Vincerx Pharma, Inc. (0001796129) (Filer)
360dSEC
SEC Form 25 filed by Vincerx Pharma Inc.
25 - Vincerx Pharma, Inc. (0001796129) (Filer)